Table 1. Baseline characteristics of the study cohort (n = 162).
| Demographics | |
| Age (years) | 52.6±18.2 |
| Gender (male) | 88 (54) |
| Caucasian patients | 86 (53) |
| Body Mass Index (kg/m2) | 25.4±4.8 |
| Hypertension | 79 (48) |
| Hyperlipidemia* | 37 (22) |
| Diabetes | 17 (10) |
| Cancer** | 25 (15) |
| Etiology of CKD | |
| FSGS/minimal changes disease | 23 (14) |
| ANCA-mediated vasculitidis | 15 (9) |
| IgA nephropathy | 14 (8.5) |
| Primary Glomerulonephritis | 14 (8.5) |
| Lupus | 11 (6.5) |
| Diabetes | 10 (6) |
| Tubule-interstitial nephropathy | 10 (6) |
| Hypertensive nephropathy | 10 (6) |
| Non specific*** | 10 (6) |
| Myeloma cast nephropathy | 9 (5.5) |
| Other | 36 (22) |
| Medications | |
| ACEI/ARB | 69 (43) |
| Diuretics | 27 (17) |
| Beta blockers | 19 (12) |
| Calcium Channel Inhibitors | 37 (23) |
| Others | 7 (4) |
| Clinical Chemistry | |
| Serum creatinine (mg/dl) | 2.08±1.45 |
| eGFR (ml/min/1.73 m2) | 47.4±33.3 |
| Proteinuria (g/l) | 2.3±2.7 |
| Albuminuria (g/l) | 1.3±2.4 |
Continuous variables are expressed as the mean ± sem; categorical variables are expressed as n (%).
Hyperlipidemia: total cholesterol >200 mg/dl and/orTriglycerides >200 mg/dl, and/or LDL cholesterol>130 mg/dl.
Cancer: Multiple myemoma ( = 13), Urogenital ( = 7), Breast ( = 2), Lung ( = 1).
Non specific: no diagnosis, moderate interstitial fibrosis and/or glomerulosclerosis.